GlassScriptPhysician profile
Stephen D Coleman
NPI 1891720124
$7,810.34
in general payments reported to CMS, 2019-2025
53 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,687 · 2020: $379 · 2021: $774 · 2022: $888 · 2023: $1,213 · 2024: $1,312 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,082.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,741.91 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,521.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $528.36 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $508.62 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Viiv Healthcare Company | $382.60 | 2022-2025 | Apretude |
| Gilead Sciences, INC. | $293.13 | 2020-2025 | |
| Novo Nordisk INC | $288.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $235.12 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $208.49 | 2019-2025 | Repatha, Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $189.00 | 2019-2025 | Spravato |
| Merck Sharp & Dohme LLC | $137.06 | 2020-2024 | Gardasil, Vaxelis, Gardasil 9 |
| Abbott Laboratories | $122.64 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Dynavax Technologies Corporation | $112.28 | 2020-2025 | Heplisav-B |
| Boston Scientific Corporation | $109.10 | 2019-2025 | Wavewriter Alpha Prime 16, Watchman Flx |
| Supernus Pharmaceuticals, INC. | $104.36 | 2021-2024 | Qelbree, Qelbree |
Show all 52 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.